Table 3.
Histone Deacetylase Inhibitors in Clinical Trials (partial list)*
| Drug Name | Structure | Potency (in vitro) | Clinical Trials |
|---|---|---|---|
| Vorinosat (SAHA, Zolinza) |  |
μMol/L | FDA approved - CTCL, PhII–III (p.o.) |
| Panobinostat (LBH589) |  |
nMol/L | PhI–II (p.o.), PhII (i.v.) |
| Belinostat (PXD101) |  |
μMol/L | PhII (i.v.), PhI (p.o.) |
| ITF-2357 |  |
nMol/L | PhI–II (p.o.) |
| PCI-24781 (CRA-024781) |  |
NA | PhI (p.o.) |
| Romidepsin (Depsipeptide, FK228) |  |
nMol/L | PhI–II (i.v.) |
| Valproic acid |  |
mMol/L | PhII–III (p.o.), PhII (p.o.) |
| Phenylbutyrate (VP-101, EL- 532) |  |
mMol/L | PhII (p.o.) |
| Pivanex (AN-9) |  |
mMol/L | PhI–II (i.v.) |
| SB-939 |  |
μMolL | PhI (p.o.) |
| Entinostat (MS-275, SNDX-275) |  |
μMol/L | PhI–II (p.o.) |
| MGCD0103 |  |
μMol/L | PhI–II (p.o.) |
| JHJ-26481585 |  |
μMol/L | PhI–II (p.o.) |
*
See text for references.